5002572025-10-012025-12-315002572025-12-315002572025-04-012025-12-315002572025-10-012025-12-31in-capmkt:OtherExpenses1Member5002572025-10-012025-12-31in-capmkt:OtherExpenses2Member5002572025-04-012025-12-31in-capmkt:OtherExpenses1Member5002572025-04-012025-12-31in-capmkt:OtherExpenses2Member5002572025-10-012025-12-31in-capmkt:ReportableSegments1Member5002572025-10-012025-12-31in-capmkt:ReportableSegments2Member5002572025-10-012025-12-31in-capmkt:ReportableSegments3Member5002572025-04-012025-12-31in-capmkt:ReportableSegments1Member5002572025-04-012025-12-31in-capmkt:ReportableSegments2Member5002572025-04-012025-12-31in-capmkt:ReportableSegments3Member5002572025-10-012025-12-31in-capmkt:ReportableSegments1Member5002572025-10-012025-12-31in-capmkt:ReportableSegments2Member5002572025-10-012025-12-31in-capmkt:ReportableSegments3Member5002572025-04-012025-12-31in-capmkt:ReportableSegments1Member5002572025-04-012025-12-31in-capmkt:ReportableSegments2Member5002572025-04-012025-12-31in-capmkt:ReportableSegments3Member5002572025-10-012025-12-31in-capmkt:ReportableSegments1Member5002572025-12-31in-capmkt:ReportableSegments1Member5002572025-10-012025-12-31in-capmkt:ReportableSegments2Member5002572025-12-31in-capmkt:ReportableSegments2Member5002572025-10-012025-12-31in-capmkt:ReportableSegments3Member5002572025-12-31in-capmkt:ReportableSegments3Member5002572025-10-012025-12-31in-capmkt:ReportableSegments1Member5002572025-12-31in-capmkt:ReportableSegments1Member5002572025-10-012025-12-31in-capmkt:ReportableSegments2Member5002572025-12-31in-capmkt:ReportableSegments2Member5002572025-10-012025-12-31in-capmkt:ReportableSegments3Member5002572025-12-31in-capmkt:ReportableSegments3Member5002572025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15002572025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15002572025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15002572025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares500257LUPINNOTLISTEDINE326A01037Lupin LimitedMain BoardEquity2025-04-012026-03-312026-02-122026-01-28INRMillionsQuarterlyThird quarterMulti segment2026-02-1218:30:002026-02-1220:40:00Not applicable2025-10-012025-12-31UnauditedConsolidated716752000001147000000728222000001124820000071973000003358000001143280000011498000003129600000188426000005333610000019486100000-42657000001522040000020455000001369800000341530000001180510000000001180510000012010000001300610000011755500000496000001295700000049100000913700000225.7425.670025.7425.671. The above Consolidated Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on February 12, 2026. The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. <BR> <BR> 2. The Consolidated Financial Results include the financial results of the subsidiaries, Lupin Pharmaceuticals, Inc. U.S.A., Lupin Australia Pty Limited Australia, Nanomi B.V. Netherlands, Pharma Dynamics Proprietary Limited South Africa, Hormosan Pharma GmbH Germany, Multicare Pharmaceuticals Philippines Inc. Philippines, Lupin Atlantis Holdings SA Switzerland, Lupin Healthcare UK Limited U.K., Lupin Pharma Canada Limited Canada, Generic Health Pty Limited Australia, Lupin Mexico S.A. de C.V. Mexico, Lupin Philippines Inc. Philippines, Lupin Diagnostics Limited India, Generic Health SDN. BHD. Malaysia, Lupin Inc. U.S.A., Laboratorios Grin S.A. de C.V. Mexico, Medquimica Industria Farmaceutica LTDA Brazil, Novel Laboratories, Inc. U.S.A., Lupin Research Inc. U.S.A., Lupin Management Inc. U.S.A, Lupin Europe GmbH Germany, Lupin Biologics Limited India, Lupin Oncology Inc. U.S.A, Lupin Digital Health Limited India, Avenue Coral Springs LLC U.S.A., Southern Cross Pharma Pty Ltd Australia, Lupin Life Sciences Limited India formerly known as Lupin Atharv Ability Limited India, Lupin Manufacturing Solutions Limited India, Medisol S.A.S. France, Lupin Lanka Private Ltd. Sri Lanka w.e.f. August 05, 2024, Lupin NZ Ltd. New Zealand w.e.f. August 08, 2024, Lupinlife Consumer Healthcare Limited India w.e.f. March 08, 2025, Renascience Pharma Limited U.K. w.e.f. April 02, 2025 and a joint venture, YL Biologics Limited Japan. <BR> <BR> 3. The Consolidated Financial Statements are prepared in accordance with Ind AS 110 Consolidated Financial Statements and Ind AS 28 Investments in Associates and Joint Ventures. <BR> <BR> 4. During the quarter ended December 31, 2025, 40,938 yearto date 233,761 equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans ESOPs, resulting in an increase in the paid up share capital by Rs. 0.1 million year to date Rs. 0.5 million and securities premium account by Rs. 40.9 million year to date Rs. 256.5 million. <BR> <BR> 5. Exceptional items <BR> <BR> a. Lupin Limited and its US subsidiary were named in class action and individual cases related to Antitrust Litigations for certain products. The Company intends to settle the matter with certain parties without admitting any liability for any wrongdoing and accordingly has created a provision of Rs. 4,493.9 million USD 50.0 million during the quarter and nine months ended December 31, 2025. <BR> b. On February 09, 2026, Lupin Limited and its subsidiary entered into a settlement agreement with Astellas towards ongoing dispute related to Mirabegron ER Tablets a generic version of Myrbetriq ER Tablets in US markets. The Company has agreed to pay USD 90.0 million, which includes USD 75.0 million towards Prepaid Option. During the quarter and nine months ended December 31, 2025 the Group has provided Rs. 1,348.1 million USD 15.0 million for one time payment towards this settlement. <BR> c. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 collectively referred to as the New Labour Codes. The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Group has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs. 512.2 million during the quarter and nine months ended December 31, 2025. The Group continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards. <BR> d. During the quarter and nine months ended December 31, 2025, the Group entered into a settlement agreement with an income of Rs. 873.7 million USD 10.0 million. <BR> e. During the quarter, the Group has received an arbitration award, consequently accounted an income of Rs. 603.2 million USD 6.9 million and a reversal of expense provision of Rs. 611.6 million USD 7.0 million. <BR> <BR> 6. During the nine months ended December 31, 2025, the Company through its wholly owned subsidiary Nanomi B.V., Netherlands Nanomi has entered into a definitive agreement to acquire 100 share capital of VISUfarma B.V., Netherlands, for a consideration of EUR 190.0 million subject to closing adjustments. Pending regulatory approval, no impact has been given in the results. The acquisition related costs are accounted in Other expenses. <BR> <BR> 7. During the nine months ended December 31, 2025, the Company through its wholly owned stepdown subsidiary, Lupin Healthcare UK Limited, U.K., acquired 100 equity share capital of Renascience Pharma Limited, U.K., for a consideration of Rs. 1,361.6 million GBP 12.3 million. Fair value of intangibles acquired Rs. 1,239.4 million, deferred tax liability Rs. 309.8 million, Goodwill Rs. 325.9 million has been accounted based on report of independent valuer. <BR> <BR> 8. During the nine months ended December 31, 2024 and year ended March 31, 2025, Lupin Limited and its subsidiary, agreed to settle the dispute for an amount of USD 9.0 million Rs. 750.5 million in connection with the drug Glumetza without admitting any liability for any wrongdoing, with a view to avoid the costs and uncertainties of continued litigation. <BR> <BR> 9. During the year ended March 31, 2025, the Group has recognised an impairment charge of Rs. 1,209.0 million related to certain property, plant and equipment, capital workinprogress, intangible assets, intangible assets under development and goodwill. <BR> 2025-04-012025-12-31UnauditedConsolidated20483370000028374000002076711000003390600000021586000000-74370000033318300000314330000092871000005346270000015395970000053711400000-42657000004944570000010194300000383200000105775000000388682000000000388682000003761400000426296000003872520000014300000042465100000164500000913700000284.7984.560084.7984.56Other expenses19366200000Net (gain) / loss on foreign currency transactions-523600000Other expenses56882300000Net (gain) / loss on foreign currency transactions-3419600000Pharmaceuticals71308900000Others369600000Less: Inter segment0Pharmaceuticals203776200000Others1069200000Less: Inter segment07167850000020484540000033000001170000071675200000204833700000Pharmaceuticals15673500000Others-453100000Less: Inter segment0Pharmaceuticals50731900000Others-1286200000Less: Inter segment015220400000494457000001522040000049445700000Pharmaceuticals349748600000Others2530900000Less: Inter segment-379000003522416000000352241600000Pharmaceuticals140946600000Others998400000Less: Inter segment-365000001419085000000141908500000Items that will not be reclassified subsequently to profit or loss-59300000-59300000Items that will not be reclassified subsequently to profit or loss-69100000-69100000-27000000-20400000Items that will be reclassified subsequently to profit or loss12288000001228800000Items that will be reclassified subsequently to profit or loss36780000003678000000-4500000-13210000012010000003761400000